Cardinal Health Inc. (CAH)
CAH Stock Rises More Than 13% YTD: Should You Buy, Hold or Sell?
Cardinal Health's recent acquisitions and GMPD recovery look promising. However, the loss of the Optum Rx contract and margin pressure are likely to hurt short-term prospects.
Cardinal Health (CAH) Ascends While Market Falls: Some Facts to Note
Cardinal Health (CAH) closed at $133.98 in the latest trading session, marking a +0.93% move from the prior day.
Why Cardinal Health (CAH) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Cardinal Health, Inc. (CAH) Hits Fresh High: Is There Still Room to Run?
Cardinal (CAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Cardinal Health (CAH) Stock Drops Despite Market Gains: Important Facts to Note
Cardinal Health (CAH) concluded the recent trading session at $132.75, signifying a -0.35% move from its prior day's close.
Cardinal Health, Inc. (CAH) Leerink's 2025 Global Healthcare Conference (Transcript)
Cardinal Health, Inc. (NYSE:CAH ) Leerink's 2025 Global Healthcare Conference Call March 12, 2025 8:40 AM ET Company Participants Aaron Alt - Chief Financial Officer Matt Sims - Investor Relations Conference Call Participants Mike Cherny - Leerink Mike Cherny Perfect. We'll get started here.
Watch These 3 Stocks for Solid Earnings Acceleration
Prairie Operating, Intuit and Cardinal Health are exhibiting strong earnings acceleration.
Are Investors Undervaluing Cardinal Health (CAH) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Should Value Investors Buy Cardinal Health (CAH) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Cardinal Health Analysts Raise Their Forecasts Following Upbeat Earnings
Cardinal Health CAH reported better-than-expected second-quarter financial results on Thursday.
Cardinal Health, Inc. (CAH) Q2 2025 Earnings Call Transcript
Cardinal Health, Inc. (NYSE:CAH ) Q2 2025 Earnings Conference Call January 30, 2025 8:30 AM ET Company Participants Matt Sims - Vice President, Investor Relations Jason Hollar - Chief Executive Officer Aaron Alt - Chief Financial Officer Conference Call Participants John Stansel - JPMorgan Erin Wright - Morgan Stanley Allen Lutz - Bank of America Elizabeth Anderson - Evercore Michael Cherny - Leerink Partners Eric Percher - Nephron Kevin Caliendo - UBS Eric Coldwell - Baird Daniel Grosslight - Citi Steven Valiquette - Mizuho Charles Rhyee - TD Cowen Brian Tanquilut - Jefferies Operator Hello, and welcome to the Second Quarter Fiscal Year 2025 Cardinal Health Inc. Earnings Conference Call. My name is George, and I'll be coordinator for today's event.
CAH Q2 Earnings and Sales Beat Estimates, 2025 EPS View Raised
Cardinal Health's second-quarter fiscal 2025 results benefit from solid Other segment revenue growth. However, OptumRx contract expiry hurts Pharmaceutical segment sales.
